Clinical Trial: Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)

U.S., Aug. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07778316) titled 'Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)' on Aug. 12.

Brief Summary: The primary objective of this study is to demonstrate non-inferiority in pharmacokinetic (PK) parameters of subcutaneous (SC) vs intravenous (IV) tarlatamab administration and to characterize the efficacy, safety, and tolerability of SC tarlatamab in participants with relapsed extensive-stage small-cell lung cancer (ES-SCLC) after platinum-based chemotherapy.

Study Start Date: Aug. 31

Study Type: INTERVENTIONAL

Condition: Small Cell Lung Cancer

Intervention: DRUG: T...